{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:31:15Z","timestamp":1793359875790,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dialogues in Health"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.dialog.2026.100354","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:03:27Z","timestamp":1790265807000},"page":"100354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Is India ready for controlled human infection studies? A narrative review of stakeholders' perceptions & regulatory preparedness"],"prefix":"10.1016","volume":"9","author":[{"given":"Shreya","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Niveditha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dialog.2026.100354_bb0005","series-title":"Key criteria for the ethical acceptability of controlled human infection studies during public health emergencies","author":"World Health Organization","year":"2025"},{"key":"10.1016\/j.dialog.2026.100354_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-015-0671-x","article-title":"Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya","volume":"14","author":"Hodgson","year":"2015","journal-title":"Malar. J."},{"issue":"1","key":"10.1016\/j.dialog.2026.100354_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-35752-x","article-title":"Perceptions and acceptability of the controlled human malaria infection (CHMI) model in The Gambia: a qualitative study","volume":"13","author":"Dabira","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.dialog.2026.100354_bb0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.12688\/wellcomeopenres.12256.1","article-title":"Wellcome Trust CHIM workshop participants. A framework for controlled human infection model (CHIM) studies in Malawi: report of a Wellcome Trust workshop on CHIM in low income countries held in Blantyre, Malawi","volume":"2","author":"Gordon","year":"2017","journal-title":"Wellcome Open Res."},{"issue":"1","key":"10.1016\/j.dialog.2026.100354_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12910-024-01160-7","article-title":"Experiences, perceptions and ethical considerations of the malaria infection study in Thailand","volume":"26","author":"Naemiratch","year":"2025","journal-title":"BMC Med Ethics."},{"key":"10.1016\/j.dialog.2026.100354_bb0030","unstructured":"ICMR Controlled Human Infection Studies Policy Document 2023. Available from: https:\/\/ main. icmr.nic. in\/ sites\/ defau lt\/ files\/ upload_ documents\/ ICMR_ CHIS _Policy_Document.pdf."},{"issue":"1","key":"10.1016\/j.dialog.2026.100354_bb0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s40592-020-00121-1","article-title":"Public perceptions on controlled human infection model (CHIM) studies\u2014a qualitative pilot study from South India","volume":"39","author":"Vaz","year":"2021","journal-title":"Monash Bioeth Rev"},{"issue":"1","key":"10.1016\/j.dialog.2026.100354_bb0040","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s40592-025-00231-8","article-title":"Perceptions of members of ethics committees of medical institutions in India on controlled human infection studies (CHIS) following a sensitization workshop: a systematic survey","volume":"43","author":"Lakshminarayanan","year":"2025","journal-title":"Monash Bioeth Rev"},{"key":"10.1016\/j.dialog.2026.100354_bb0045","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.17968.2","article-title":"Perceptions about controlled human infection model (CHIM) studies among members of ethics committees of Indian medical institutions: a qualitative exploration","volume":"7","author":"Sharma","year":"2023","journal-title":"Wellcome Open Res"},{"issue":"1","key":"10.1016\/j.dialog.2026.100354_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltaf004","article-title":"Human challenge models for vaccine development-strengths, limitations, and expansion into endemic settings: a HIC-Vac meeting report","volume":"5","author":"Wagstaffe","year":"2025","journal-title":"Immunother Adv."},{"key":"10.1016\/j.dialog.2026.100354_bb0055","author":"The New Drugs and Clinical Trials Rules 2019"},{"issue":"3&4","key":"10.1016\/j.dialog.2026.100354_bb0060","doi-asserted-by":"crossref","first-page":"262","DOI":"10.25259\/IJMR_985_2024","article-title":"Ethics & utility of controlled human infection studies (CHIS) in low- & middle-income countries","volume":"160","author":"Eberts","year":"2024","journal-title":"Indian J. Med. Res."},{"issue":"4","key":"10.1016\/j.dialog.2026.100354_bb0065","first-page":"263","article-title":"Conducting controlled human infection model studies in India is an ethical obligation","volume":"3","author":"Dholakia","year":"2018","journal-title":"Indian J Med Ethics"},{"issue":"5","key":"10.1016\/j.dialog.2026.100354_bb0070","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/infdis\/jiaf053","article-title":"Controlled human infection studies accelerate vaccine development","volume":"231","author":"Laurens","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.dialog.2026.100354_bb0075","series-title":"66th annual meeting of the American Society of Tropical Medicine and Hygiene. Am J Trop Med Hyg","first-page":"594","article-title":"High level efficacy in humans of a next-generation Plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-m adjuvant","volume":"97","author":"Venkatraman","year":"2017"},{"issue":"8","key":"10.1016\/j.dialog.2026.100354_bb0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1473-3099(24)00153-1","article-title":"Lessons for dengue vaccines from a human challenge study","volume":"24","author":"Ooi","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"10.1016\/j.dialog.2026.100354_bb0085","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.dialog.2026.100354_bb0090","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1093\/cid\/ciad382","article-title":"Ethics of controlled human infection studies with hepatitis C virus","volume":"77","author":"Rid","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"10111","key":"10.1016\/j.dialog.2026.100354_bb0095","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.dialog.2026.100354_bb0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018 - recommendations","volume":"37","author":"World Health Organization","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.dialog.2026.100354_bb0105","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","article-title":"Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites","volume":"91","author":"Shekalaghe","year":"2014","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.dialog.2026.100354_bb0110","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.23277.2","article-title":"Considerations in planning a controlled human infection model in at-risk groups in sub-Saharan Africa: the case for pneumococcal challenge in people living with HIV in Malawi and a report of stakeholder consultation","volume":"9","author":"Doherty","year":"2025","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.dialog.2026.100354_bb0115","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.19271.2","article-title":"Recruitment strategies used to enrol healthy volunteers in the first pneumococcal human infection study in Africa: lessons from Blantyre, Malawi","volume":"9","author":"Nsomba","year":"2025","journal-title":"Wellcome Open Res."},{"issue":"3","key":"10.1016\/j.dialog.2026.100354_bb0120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/17470161251355985","article-title":"How community members in Uganda perceive controlled human infection studies","volume":"22","author":"Nazziwa","year":"2026","journal-title":"Res. Ethics"},{"key":"10.1016\/j.dialog.2026.100354_bb0125","author":"Guidelines for Good Clinical Practices"},{"key":"10.1016\/j.dialog.2026.100354_bb0130","author":"The WORKMEN COMPENSATION ACT"},{"key":"10.1016\/j.dialog.2026.100354_bb0135","author":"THE MOTOR VEHICLE ACT"}],"container-title":["Dialogues in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772653326000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772653326000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:38:49Z","timestamp":1793356729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772653326000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"alternative-id":["S2772653326000791"],"URL":"https:\/\/doi.org\/10.1016\/j.dialog.2026.100354","relation":{},"ISSN":["2772-6533"],"issn-type":[{"value":"2772-6533","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is India ready for controlled human infection studies? A narrative review of stakeholders' perceptions & regulatory preparedness","name":"articletitle","label":"Article Title"},{"value":"Dialogues in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dialog.2026.100354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100354"}}